Cascade Financial Partners LLC Sells 236 Shares of Illumina, Inc. (NASDAQ:ILMN)

Cascade Financial Partners LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,499 shares of the life sciences company’s stock after selling 236 shares during the quarter. Cascade Financial Partners LLC’s holdings in Illumina were worth $334,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Versant Capital Management Inc grew its stake in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new stake in Illumina in the fourth quarter worth $32,000. Assetmark Inc. increased its position in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina during the fourth quarter worth $45,000. Finally, TD Private Client Wealth LLC increased its position in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Down 1.7 %

Shares of NASDAQ ILMN opened at $84.52 on Wednesday. The company has a market capitalization of $13.39 billion, a P/E ratio of -11.01, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52-week low of $80.18 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company’s 50 day moving average price is $116.45 and its 200-day moving average price is $130.84.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ILMN shares. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Citigroup cut their target price on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Guggenheim cut their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Robert W. Baird dropped their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Finally, TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $146.85.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.